Published in Curr Pharm Des on January 01, 2010
Biomarkers in development of psychotropic drugs. Dialogues Clin Neurosci (2011) 0.89
Genetics and Intervention Research. Perspect Psychol Sci (2010) 0.88
Biomarkers predicting antidepressant treatment response: how can we advance the field? Dis Markers (2013) 0.86
Personalized medicine in major depressive disorder -- opportunities and pitfalls. Metabolism (2012) 0.85
Pharmacogenomics in early-phase clinical development. Pharmacogenomics (2013) 0.83
Neural correlates of emotion regulation in the ventral prefrontal cortex and the encoding of subjective value and economic utility. Front Psychiatry (2014) 0.82
Use of magnetic resonance imaging in pharmacogenomics. Br J Clin Pharmacol (2014) 0.80
A Digital Atlas of Middle to Large Brain Vessels and Their Relation to Cortical and Subcortical Structures. Front Neuroanat (2016) 0.79
The promises of personalized medicine. Eur J Clin Pharmacol (2010) 0.78
Challenges in pharmacogenetics. Eur J Clin Pharmacol (2013) 0.76
Changes in prefrontal-limbic function in major depression after 15 months of long-term psychotherapy. PLoS One (2012) 1.75
Genetic variants in FKBP5 affecting response to antidepressant drug treatment. Pharmacogenomics (2008) 1.12
Habitual emotion regulation strategies and baseline brain perfusion. Neuroreport (2008) 0.99
Baseline brain perfusion and the serotonin transporter promoter polymorphism. Biol Psychiatry (2009) 0.98
Neural correlates of psychotherapy in anxiety and depression: a meta-analysis. PLoS One (2013) 0.91
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta (2006) 0.90
Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology (2011) 0.89
Neural correlates of erotic stimulation under different levels of female sexual hormones. PLoS One (2013) 0.88
Sex-specific differences in side effects of psychotropic drugs: genes or gender? Pharmacogenomics (2009) 0.87
Impact of CYP2D6*4 genotype on progression free survival in tamoxifen breast cancer treatment. Curr Med Res Opin (2010) 0.86
Baseline brain perfusion and working memory capacity: a neuroimaging study. Neuroreport (2008) 0.85
Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur J Clin Pharmacol (2011) 0.85
A clinical case study of a psychoanalytic psychotherapy monitored with functional neuroimaging. Front Hum Neurosci (2013) 0.84
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients? Antivir Ther (2010) 0.82
Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage (2011) 0.81
Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors. Expert Opin Drug Metab Toxicol (2015) 0.79
Transcranial magnetic stimulation in motor conversion disorder: a short case series. J Clin Neurophysiol (2006) 0.79
Variability in transport and biotransformation of cytarabine is associated with its toxicity in peripheral blood mononuclear cells. Pharmacogenomics (2011) 0.79
Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study. Neuroimage (2012) 0.78
Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal Biochem (2009) 0.78
Emotional and cognitive processing of narratives and individual appraisal styles: recruitment of cognitive control networks vs. modulation of deactivations. Front Hum Neurosci (2012) 0.78
Imputation techniques for the detection of microstructural changes in schizophrenia, with an application to magnetization transfer imaging. Schizophr Res (2011) 0.76
CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. Pharmacogenomics (2015) 0.76